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Abstract: 
Purpose Two cases of malignant hyperthermia suspected to be related to the use of a nondepolarizing 
neuromuscular blocker are reported.  
Summary A pharmacogenetic disorder that may occur in as many as 1 in 3000 anesthesia procedures, 
malignant hyperthermia has been linked to the use of certain anesthetic gases and depolarizing 
neuromuscular blocking agents (e.g., succinylcholine). Although nondepolarizing neuromuscular blockers 
were cited as contributing to the development of malignant hyperthermia in a small number of published 
reports, the agents are generally considered safe for use in at-risk patients. Here investigators report two 
cases in which the nondepolarizing agent rocuronium is thought to have triggered malignant hyperthermia 
in patients with no known history of the disorder. In one case, a critically ill 27-year-old man undergoing 
an induced-hypothermia protocol developed a fever about 4 days after receiving rocuronium infusions, 
with temperatures rising over 11 days to a maximum of 105.2 °F. In the other case, a 63-year-old man 
being treated for serious complications of elective surgery developed extreme fever (maximum 
temperature of 107.1 °F) about 4 days after receiving two bolus doses and a continuous infusion of 
rocuronium. In both cases, the discontinuation of rocuronium therapy was followed by the rapid 
diminution of fever over 12–36 hours. After consultations with medical staff and consideration of other 
potential causal and contributory factors (e.g., neurologic injury, antimicrobial-induced fever), 
rocuronium was deemed the most likely trigger of the severe febrile response experienced by these two 
patients.  
Conclusion A 27-year-old man and a 63-year-old man received rocuronium and subsequently developed 
delayed-onset malignant hyperthermia, which resolved after the rocuronium was discontinued.  
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Malignant hyperthermia, an inherited, autosomal-dominant disorder of skeletal muscle, is 
triggered by certain anesthetic gases and neuromuscular blocking agents.1–9 There are several 
theories regarding the pathophysiology of this adverse reaction, which has been most often 
reported in association with the use of depolarizing neuromuscular blockers such as 
succinylcholine.  
Succinylcholine produces transient muscle paralysis by acting on postsynaptic receptors, leading 
to depolarization of the sarcolemmal membrane; according to one theory on the etiology of 
malignant hyperthermia, this depolarization opens the dihydropyridine voltage-gated calcium 
channels, causing the ryanodine-receptor channels to release calcium and resulting in muscle 
contraction and markedly elevated body temperatures.1,2 Another theorized etiologic mechanism 
for malignant hyperthermia focuses on the proliferation of acetylcholine receptors in genetically 
susceptible patients. When succinylcholine is administered, an unusually high signal input to the 
ryanodine-receptor channels causes even larger amounts of calcium release, further potentiating 
malignant hyperthermia.1 
The physical manifestations of malignant hyperthermia result from an uncontrolled release of 
intracellular calcium from skeletal muscle sarcoplasmic reticulum.1–3 This increase in intracellular 
calcium leads to sustained hypermetabolism, resulting in muscle contraction, increased 
consumption of oxygen, production of carbon dioxide, breakdown of adenosine triphosphate, and 
increased heat production.2–5 These metabolic changes manifest in the typical signs and symptoms 
of malignant hyperthermia, including a rapid rise in end tidal carbon dioxide, generalized and 
masseter-muscle rigidity, hyperthermia, tachycardia, tachypnea, rhabdomyolysis, respiratory and 
metabolic acidosis, myoglobinuria, increased creatinine kinase levels, and hyperkalemia.2–5 
Nondepolarizing neuromuscular blockers act by competing for cholinergic receptors at the motor 
end plate, a mechanism very different from that of succinylcholine. The occurrence of malignant 
hyperthermia with the administration of either benzylisoquinolinium or aminosteroidal 
nondepolarizing neuromuscular blockers is not well established.10–13 Therefore, the use of 
nondepolarizing neuromuscular blockers, particularly aminosteroidal neuromuscular blockers 
such as rocuronium, is generally considered safe in patients at risk for malignant hyperthermia.1–
3,6,14 Here we describe two patients in whom rocuronium was the most likely trigger for the 
development of malignant hyperthermia.  
Case reports 
Patient 1 
A 27-year-old Caucasian man (weight, 70 kg; height, 178 cm) with a history of alcohol, tobacco, 
and illicit drug use was taken to the hospital after being found unconscious for an unknown period 
of time. Emergency medical services found the patient asystolic. Advanced cardiac life support 
was initiated, including endotracheal intubation, cardiopulmonary resuscitation, i.v. epinephrine 
therapy, and i.v. atropine therapy. Spontaneous circulation returned with sinus tachycardia rhythm. 
On the patient’s arrival at the hospital, laboratory measures were notable for a urine drug screen 
positive for opioids and tetrahydrocannabinol and anion-gap metabolic acidosis. Arterial blood gas 
measurements revealed the following: pH, 7.04; partial pressure of carbon dioxide (pCO2), 77 mm 
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Hg; partial pressure of oxygen (pO2), 26 mm Hg; and bicarbonate concentration, 20.9 mmol/L. 
The neurologic examination revealed 2-mm round pupils that were sluggishly reactive to light. 
The patient was admitted to the intensive care unit (ICU), where a 48-hour hypothermia procedure 
was initiated per institutional protocol using external cooling devices to achieve a target 
temperature of 91.4 °F with continuous bladder temperature monitoring.15 During the initial 48 
hours, a propofol infusion (titrated to achieve a bispectral index score of 40–60) and a rocuronium 
infusion (initiated at 8 μg/kg/min and titrated to achieve a train-of-four score of 2) were used to 
manage shivering during the induction of the hypothermia protocol.16 The rocuronium infusion 
was discontinued on hospital day 2 on completion of the rewarming process, and no shivering was 
noted; however, the patient developed acute respiratory distress syndrome (ARDS) with ventilator 
asynchrony requiring the reinitiation of the rocuronium infusion on the same day and prone 
positioning (initiated on day 3 of hospitalization) for alveoli recruitment.17 On hospital day 6, an 
initial elevated axillary temperature of 101.4 °F occurred. An infectious diseases consultation was 
obtained, which resulted in the initiation of broad-spectrum antibiotics including piperacillin–
tazobactam 4.5 g i.v. every 6 hours, vancomycin 1 g i.v. every 12 hours, and fluconazole 200 mg 
i.v. every 24 hours. The patient continued to demonstrate a rise in temperature, to a maximum of 
105.2 °F, through hospital day 9 (Figure 1). The patient had a white blood cell (WBC) count of 
10,500/mm3. On evaluation by physician specialists in infectious diseases, including an assessment 
of culture results and all sites of catheter placement, no source of infection was identified. 
Although piperacillin–tazobactam has been associated with drug- induced fever,18 the infectious 
diseases specialists determined this agent to be an unlikely cause of the patient’s fever, and therapy 
was continued. Other concurrent medications were critically reviewed for possible causation of 
the febrile response. These medications included fluconazole; vancomycin; propofol, lorazepam, 
and fentanyl i.v. continuous infusion; methylprednisolone 40 mg i.v. every 8 hours; insulin 
infusion (titrated to achieve a blood glucose concentration of 90–130 mg/dL); diltiazem 
hydrochloride 5 mg/hr i.v.; famotidine 20 mg i.v. every 12 hours; enoxaparin sodium 40 mg 
subcutaneously every 24 hours; acetaminophen 650 mg via a feeding tube every 4 hours as needed 
(i.e., for a temperature of >101.5 °F); and indomethacin 50 mg via a feeding tube every 12 hours 
as needed (i.e., for a temperature of >101 °F unresponsive to acetaminophen therapy). Physician 
specialists in infectious diseases, pulmonology, and neurology determined that these concurrent 
medications were highly unlikely to be causative agents, and no changes to medication therapy 
were ordered. Other complications at the time of the occurrence of malignant hyperthermia 
included hypertension (153/90 mm Hg), anoxic encephalopathy, elevated creatine phosphokinase 
(351 units/L), and resolving hypernatremia (150 mmol/L). Rocuronium was discontinued at 11 
a.m. on hospital day 10 due to a suspicion of drug-induced malignant hyperthermia. One hour after 
the discontinuation of the neuromuscular blocker, the patient’s temperature began to decline, 
reaching a nadir of 99.4 °F by day 11 of the hospitalization (Figure 1). The patient’s fever did not 
return. Due to the close temporal relationship of the patient’s temperature decline and the 
discontinuation of rocuronium, he was believed by the physician specialists to have experienced 
malignant hyperthermia consequent to rocuronium use.  
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Figure 1 Sequential temperature measurements for patient 1 (panel A) and patient 2 (panel B), with the points of rocuronium 
initiation and discontinuation indicated in green and red. 
Patient 2 
A 63-year-old Caucasian man (weight, 90 kg; height, 173 cm) was admitted to the hospital for the 
surgical repair of a paraesophageal hernia, which included herniation of the stomach, colon, and 
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pancreas. He was taken to the operating room on day 1 of the hospitalization, and an open reduction 
of the paraesophageal hernia was performed and deemed successful. Postoperatively, the patient 
experienced respiratory failure and declining mental status while in the recovery room. He was 
subsequently reintubated and transferred to the ICU. After the transfer, the patient developed 
hemodynamic instability and was noted to have lactic acidosis. Arterial blood gas measurements 
revealed a pH of 7.23, a pCO2 of 62 mm Hg, a pO2 of 239 mm Hg, and a bicarbonate concentration 
of 26 mmol/L. Broad-spectrum antimicrobial therapy with meropenem 500 mg i.v. every 8 hours 
was initiated empirically for potential sepsis, a low-grade fever (100.2 °F), and the presence of a 
left shift of the WBC count (2800/mm3, with neutrophil bands of 58%). The patient also received 
volume resuscitation with 0.9% sodium chloride and norepinephrine (i.v. continuous infusion 
titrated to achieve a mean arterial pressure of >65 mm Hg) due to his hemodynamic instability. 
During the patient’s second hospital day a rocuronium infusion (initiated at 8 μg/kg/min and 
titrated to a train-of-four score of 2) was started for the management of ventilator asynchrony after 
other pharmacologic measures, including lorazepam 2 mg/hr by i.v. continuous infusion and 
fentanyl i.v. continuous infusion, were exhausted. On hospital day 4, the patient developed 
abdominal compartment syndrome and was returned to the operating room for decompression. 
During surgery, the patient received desflurane (2.1–3%) and two 50-mg bolus doses of 
rocuronium in addition to the continuous infusion of rocuronium. Intraoperatively, the patient 
experienced cardiac arrest with pulseless electrical activity requiring chest compressions and the 
use of epinephrine and atropine. The patient regained spontaneous circulation and was returned to 
the ICU, with the continuation of the rocuronium infusion. The patient was diagnosed with ARDS 
and septic shock on day 5 of the hospitalization. Anidulafungin 100 mg i.v. every 24 hours, 
vancomycin 1500 mg i.v. every 24 hours, ciprofloxacin 400 mg i.v. every 12 hours, and activated 
drotrecogin alfa 24 μg/kg/hr i.v. continuous infusion for 96 hours were initiated for the treatment 
of sepsis, in addition to prone positioning for alveoli recruitment. On hospital day 8, the patient 
returned to the operating room a third time for the replacement of the temporary abdominal 
closures and the placement of a negative-pressure wound therapy device. The rocuronium infusion 
was continued throughout the procedure and after the patient’s return to the ICU. Postoperatively, 
fever was immediately noted, with temperatures continuing to rise through hospital day 8 to a 
maximum of 107.1 °F (Figure 1). Considering the pattern of the recorded temperature values, the 
infectious diseases specialists did not believe the patient’s febrile response had an infectious 
etiology, believing instead that it likely resulted from neurologic injury or was medication related. 
Antimicrobial therapy was changed due to the continued suspicion of drug-related fever after all 
other potential sources of infection were evaluated and the patient’s catheter was removed. 
Meropenem, vancomycin, and ciprofloxacin were discontinued, and tigecycline 100 mg i.v. every 
24 hours was initiated. Other concurrent medications were critically reviewed for possible 
causation of the febrile response; those medications included drotrecogin alfa (activated), fentanyl, 
lorazepam, total parenteral nutrition, nebulized albuterol, nebulized acetylcysteine 20%, 
pantoprazole 40 mg i.v. every 24 hours, amiodarone (a 150-mg i.v. bolus followed by a 750-mg 
i.v. infusion), norepinephrine (titrated to maintain a mean arterial pressure of >65 mm Hg), 
vasopressin 0.03 unit/min by i.v. continuous infusion, and a regular insulin infusion titrated to 
achieve a blood glucose concentration of 90–130 mg/dL. Atrial fibrillation was present at the time 
of the febrile response, with the serum potassium concentration (4.2 mmol/L) noted to be within 
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normal limits. Neurology specialists were consulted for the evaluation and management of what 
was believed to be a malignant hyperthermia event. At that time, the rocuronium was discontinued, 
and the patient was treated with dantrolene sodium (an initial dose of 200 mg followed by 100 mg 
i.v. every 6 hours) and bromocriptine (2.5 mg per gastrointestinal tube every 8 hours) for the 
presumptive treatment of malignant hyperthermia. Twelve hours after the discontinuation of 
rocuronium, the patient’s temperature began to decline; a nadir of 97.7 °F was achieved 18 hours 
after the discontinuation of rocuronium and 4 hours after the first doses of dantrolene and 
bromocriptine were administered (Figure 1). The fever did not return, and both dantrolene and 
bromocriptine were discontinued after 48 hours of treatment. As a result of the temporal 
relationship between the patient’s temperature decline and the discontinuation of rocuronium (and 
the initiation of dantrolene and bromocriptine), the patient was believed by physician specialists 
to have experienced malignant hyperthermia as a result of rocuronium use.  
Discussion 
Cases of malignant hyperthermia have increased in the United States in recent years, with an 
estimated occurrence of up to 1 in 3000 patients undergoing anesthesia procedures.6,19 Men appear 
to be more likely to suffer an episode of malignant hyperthermia; however, women are at higher 
risk for dying from the disorder. Associated mortality rates in adults range from 6.5% to 16.9%, 
while children have a much lower mortality rate (0.7%).19 
Genetic predisposition to malignant hyperthermia was not considered in the two cases described 
here, as neither patient had a known personal or family history of the disorder. Many susceptible 
patients can receive multiple “trigger” agents without developing malignant hyperthermia.1 
Therefore, previous exposure to nondepolarizing neuromuscular blockers does not preclude a 
suspicion of drug-induced malignant hyperthermia with subsequent exposures.  
Malignant hyperthermia may occur at any point during and after anesthesia administration, 
although it is most common within 140 minutes after the administration of halogenated anesthetics 
and within 35 minutes of the administration of a depolarizing neuromuscular blocker.2,7 In the 
second case reported here, the patient was exposed to an anesthetic gas, but malignant 
hyperthermia developed more than four days after the exposure; based on the delayed onset, the 
anesthetic gas was not believed to be responsible for the development of malignant hyperthermia 
in this patient.  
Although the majority of published reports indicate that the use of depolarizing neuromuscular 
blockers can trigger malignant hyperthermia in susceptible patients, a small number of case reports 
suggest the possibility that nondepolarizing neuromuscular blockers may be contributing agents.10–
13 Polta et al.10 described the development of isolated masseter-muscle spasm—a common finding 
in patients experiencing malignant hyperthermia and a risk factor for the development of the 
disorder—after the administration of pancuronium in a 20-year-old man undergoing corrective 
surgery for congenital aortic stenosis2,10; he received pancuronium a second time during 
orotracheal intubation and experienced a recurrence of the rigidity of the jaw muscles. The patient 
recovered fully without treatment in both instances.  
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Two cases of isolated masseter-muscle rigidity with the use of a non-depolarizing neuromuscular 
blocker were reported by Albrecht and colleagues.11 In one of those cases, a 22-year-old woman 
experienced masseter-muscle rigidity after receiving atracurium. On discontinuation of anesthesia 
including thiopental, midazolam, fentanyl, isofurane, and nitrous oxide, the patient recovered fully 
without treatment. In the other case reported by Albrecht et al., a 33-year-old woman experienced 
isolated masseter-muscle rigidity after receiving vecuronium followed by atracurium and 
mivacurium. That patient also fully recovered after the discontinuation of anesthesia including 
midazolam, fentanyl, thiopental, and desflurane and the reversal of the effects of the 
neuromuscular blocker with atropine and edrophonium.  
Increased body temperature in combination with other signs of malignant hyperthermia in patients 
receiving nondepolarizing neuromuscular blockers has been documented in four case reports. 
Waterman et al.12 reported the case of a 25-year-old man with malignant hyperthermia manifesting 
as tachycardia and increased temperature five minutes after the administration of pancuronium. In 
that case, anesthesia including fentanyl, diazepam, and thiamylal sodium was abruptly 
discontinued at the time of the event, and the patient was treated with a cooling blanket, iced saline, 
droperidol, dexamethasone, and procainamide, resulting in a full recovery. During subsequent 
surgery in this patient, neuromuscular blockers were avoided, and malignant hyperthermia did not 
recur. Albrecht et al.11 reported on the case of an 11-year-old boy who received thiopental, 
atracurium, isoflurane, and nitrous oxide during an orthopedic surgical procedure. Three hours 
after receiving anesthesia, the patient experienced tachycardia, masseter-muscle rigidity, and an 
increase in temperature of <1 °C. The discontinuation of isoflurane and the administration of 
dantrolene resulted in the patient’s full recovery. In another case described in the same report, a 
49-year-old woman with a family history of anesthesia-related death developed masseter-muscle 
rigidity with a temperature increase of 1 °C during anesthesia (fentanyl, diazepam, thiopental, and 
atracurium) despite treatment with dantrolene before surgery.11 The patient experienced a full 
recovery after ice was applied for cooling. Four years later, the same patient underwent anesthesia 
with propofol, fentanyl, nitrous oxide, and vecuronium; no masseter-muscle rigidity or other 
indications of malignant hyperthermia were noted. None of these reports demonstrated a definitive 
causal relationship between the use of neuromuscular blockers and the development of malignant 
hyperthermia, as many of the patients involved received concomitantly administered anesthetic 
gases, which are well-documented potential inducers of malignant hyperthermia in susceptible 
patients.  
In the cases described in this article, the patients experienced the delayed onset of malignant 
hyperthermia after rocuronium administration. This presentation has only been suggested in one 
other reported case, that of a 28-year-old man who received fentanyl, midazolam, rocuronium, 
nitrous oxide, and desflurane in preparation for maxillofacial surgery after a motor vehicle 
accident.13 Seven hours after anesthesia induction, the patient was noted to have an elevated end 
tidal carbon dioxide concentration and an increased temperature. The patient was determined to 
have malignant hyperthermia, so surgery was not performed, desflurane was discontinued, the 
carbon dioxide canisters and anesthesia machinery were changed, a cooling blanket was applied, 
and dantrolene, cold i.v. fluids, and diuresis were administered. Surgery was attempted again, with 
dantrolene administration one day before the procedure and the use of propofol, midazolam, and 
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rocuronium for anesthesia. No adverse events were reported during the second procedure. The 
authors of the case report were unable to definitively determine whether rocuronium played a role 
because dantrolene was administered prior to the subsequent administration of rocuronium.  
In the cases reported here, the application of the algorithm of Naranjo et al.20 indicated a possible 
adverse reaction to rocuronium, particularly given the temporal sequence of symptom onset with 
rocuronium initiation followed by a recognized pattern of recovery on discontinuation of the drug.  
Unfortunately, due to the complex symptomatology of critically ill patient populations, it is 
difficult to demonstrate a definitive cause for this adverse drug reaction. In the two cases described 
in this report, it is possible that other variables unrelated to rocuronium use may have led to the 
development of malignant hyperthermia. For example, rhabdomyolysis is similar to malignant 
hyperthermia in its clinical and laboratory manifestations, which can include tachycardia, 
hypercarbia, pyrexia, rigidity, and elevated creatine kinase.2 Rhabdomyolysis may have played a 
role in the cases described here, as elevations of creatine phosphokinase occurred in both patients, 
although a diagnosis of rhabdomyolysis was not made in either patient. Both patients developed 
ARDS, received prone positioning, and received concomitant corticosteroids. Although few cases 
of rhabdomyolysis induced by prone positioning have been reported, it is unknown if prone 
positioning could have precipitated a malignant hyperthermia event or other skeletal muscle 
abnormality in our patients; further, prone positioning has not been documented to affect 
temperature homeostasis.21,22 
The development of myopathies when neuromuscular blockers are administered concurrently with 
corticosteroid therapy is well documented, with necrotizing myopathies reported in some cases.23 
It is not known whether the malignant hyperthermia experienced in the two cases reported here 
may have been induced by other skeletal muscle abnormalities. Neuroleptic malignant syndrome 
and serotonin syndrome can also have a presentation similar to that of malignant hyperthermia, 
but those syndromes were not considered in our patients’ differential diagnosis because neither 
had received excessive doses of serotonergic agents or dopamine antagonists.24 
It is important to consider the temporal relationship of the two cases described here. The patients 
were hospitalized within the same month at the same institution, suggesting the possibility of an 
impure lot of rocuronium as the cause of their malignant hyperthermia; however, this was unable 
to be determined.  
Other variables that may have contributed to the hyperthermia events described in this report 
include the use of antimicrobials and brain injury resulting from cardiac arrest. Antimicrobial-
induced fever may develop at any point during the use of the drugs, although it is most commonly 
noted within six to eight days of the initiation of therapy, with recovery typically occurring soon 
after the discontinuation of therapy.18 Antimicrobial-induced fever was ruled out in our patients, 
as the febrile symptoms persisted despite changes in therapy in one of the patients and, in the other 
patient, resolved without antimicrobial manipulation. With regard to the potential role of brain 
insult in these two cases, it is possible that the observed hyperthermia was a symptom of neurally 
mediated impairment of thermoregulation as a result of the patients’ cardiac arrest15; however, in 
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light of their abrupt recovery from hyperthermia after the discontinuation of rocuronium, that 
possibility was not considered likely by the health care providers involved in the cases.  
Despite a number of potential confounding factors and the complexity of the two patients’ clinical 
courses, there was a striking correlation between the temperature decline and the discontinuation 
of rocuronium in both cases. Thus, these cases suggest that nondepolarizing neuromuscular 
blockers should be considered (along with other potential offending agents) if symptoms of 
malignant hyperthermia are suspected.  
Due to the limited published evidence regarding this adverse reaction, best practices for the 
management of at-risk patients are unclear. The maximization of adjunctive anesthesia support 
(e.g., sedative and opioid therapy) in an effort to avoid neuromuscular blockade, or at least 
minimize the dosing requirements and duration of use, may be appropriate. In addition, the early 
discontinuation of neuromuscular blockade and the administration of dantrolene and 
bromocriptine in managing suspected cases of malignant hyperthermia may be considered.  
Conclusion 
A 27-year-old man and a 63-year-old man received rocuronium and subsequently developed 
delayed-onset malignant hyperthermia, which resolved after the rocuronium was discontinued. 
Footnotes 
Dr. Powers serves on the speakers bureaus of Sage Pharmaceuticals, Hollister-Stier Laboratories, 
and Kinetic Concepts. The other authors have declared no potential conflicts of interest. 
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